Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485994 | 0.90 | KMT2A (0.49) | KMT2AACHESMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24485998 | 0.84 | KMT2A (0.37) | KMT2AACHEHSD11B1SMN1; SMN2 | |
| SCHEMBL21949965 | 0.83 | KMT2A (0.44) | KMT2AACHESMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17918971 | 0.83 | DRD2 (0.36) | PDCD1LG2CD274SMN1; SMN2ALDH1A1 | |
| SCHEMBL25124459 | 0.81 | KMT2A (0.36) | KMT2AACHEHSD11B1ALDH1A1KDM4E | |
| SCHEMBL20457908 | 0.79 | GNAI3 (0.40) | ALDH1A1 | |
| SCHEMBL4550367 | 0.78 | KMT2A (0.46) | KMT2AACHE | |
| SCHEMBL7907325 | 0.78 | KMT2A (0.49) | KMT2AACHEHSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL21675901 | 0.78 | GAA (0.33) | KMT2ASMN1; SMN2GAA | |
| SCHEMBL21688341 | 0.78 | GAA (0.33) | KMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230312504-A1 | QUINOLINE COMPOUNDS | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312504-A1 | QUINOLINE COMPOUNDS | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2023116902-A1 | SOS1 INHIBITOR | 北京望实智慧科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022135432-A1 | MACROCYCLIC HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS, AND USE THEREOF | 南京圣和药业股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3342773-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2018113771-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHODS AND USES THEIROF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2018-06-28 | — | — | WO | disclosed |
| US-9908875-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2015091889-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011039344-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | KMT2A 2433/4885PDCD1LG2 1854/4885CD274 2021/4885 |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | KMT2A 1062/4885PDCD1LG2 1483/4885CD274 1413/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | KMT2A 2806/4885PDCD1LG2 2455/4885CD274 3553/4885 |
| US-20230312504-A1 | QUINOLINE COMPOUNDS | NQO2, ABCG2, NQO1 | KMT2A 1832/4885PDCD1LG2 3581/4885CD274 4120/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KMT2A 4323/4885PDCD1LG2 2716/4885CD274 4121/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KMT2A 4343/4885PDCD1LG2 2761/4885CD274 4155/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | KMT2A 3503/4885PDCD1LG2 4267/4885CD274 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.